{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T13:57:15Z","timestamp":1794059835587,"version":"4.8.0"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2020,11,25]],"date-time":"2020-11-25T00:00:00Z","timestamp":1606262400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,11,25]],"date-time":"2020-11-25T00:00:00Z","timestamp":1606262400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005690","name":"Universit\u00e4t des Saarlandes","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005690","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharm Res"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>To provide whole-body physiologically based pharmacokinetic (PBPK) models of the potent clinical organic anion transporter (OAT) inhibitor probenecid and the clinical OAT victim drug furosemide for their application in transporter-based drug-drug interaction (DDI) modeling.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      PBPK models of probenecid and furosemide were developed in PK-Sim\u00ae. Drug-dependent parameters and plasma concentration-time profiles following intravenous and oral probenecid and furosemide administration were gathered from literature and used for model development. For model evaluation, plasma concentration-time profiles, areas under the plasma concentration\u2013time curve (AUC) and peak plasma concentrations (C\n                      <jats:sub>max<\/jats:sub>\n                      ) were predicted and compared to observed data. In addition, the models were applied to predict the outcome of clinical DDI studies.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The developed models accurately describe the reported plasma concentrations of 27 clinical probenecid studies and of 42 studies using furosemide. Furthermore, application of these models to predict the probenecid-furosemide and probenecid-rifampicin DDIs demonstrates their good performance, with 6\/7 of the predicted DDI AUC ratios and 4\/5 of the predicted DDI C\n                      <jats:sub>max<\/jats:sub>\n                      ratios within 1.25-fold of the observed values, and all predicted DDI AUC and C\n                      <jats:sub>max<\/jats:sub>\n                      ratios within 2.0-fold.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Whole-body PBPK models of probenecid and furosemide were built and evaluated, providing useful tools to support the investigation of transporter mediated DDIs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11095-020-02964-z","type":"journal-article","created":{"date-parts":[[2020,11,25]],"date-time":"2020-11-25T11:05:54Z","timestamp":1606302354000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Physiologically Based Pharmacokinetic Models of Probenecid and Furosemide to Predict Transporter Mediated Drug-Drug Interactions"],"prefix":"10.1007","volume":"37","author":[{"given":"Hannah","family":"Britz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Hanke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitchell E.","family":"Taub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhagwat","family":"Prasad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c9ric","family":"Fernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Stopfer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerie","family":"Nock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8372-1465","authenticated-orcid":false,"given":"Thorsten","family":"Lehr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,11,25]]},"reference":[{"issue":"5","key":"2964_CR1","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1007\/s13238-015-0148-2","volume":"6","author":"Y Liang","year":"2015","unstructured":"Liang Y, Li S, Chen L. The physiological role of drug transporters. Protein Cell. 2015;6(5):334\u201350.","journal-title":"Protein Cell"},{"key":"2964_CR2","unstructured":"U.S. Food and Drug Administration. In Vitro Drug Interaction Studies - Cytochrome P450 Enzyme- and Transporter-Mediated Drug Interactions. Guidance for Industry. 2020."},{"key":"2964_CR3","unstructured":"European Medicines Agency. Guideline on the investigation of drug interactions. 2015."},{"issue":"4","key":"2964_CR4","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1681\/ASN.V134866","volume":"13","author":"H Motohashi","year":"2002","unstructured":"Motohashi H, Sakurai Y, Saito H, Masuda S, Urakami Y, Goto M, et al. Gene expression levels and immunolocalization of organic ion transporters in the human kidney. J Am Soc Nephrol. 2002;13(4):866\u201374.","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"2964_CR5","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1124\/dmd.116.074294","volume":"45","author":"S Mathialagan","year":"2017","unstructured":"Mathialagan S, Piotrowski MA, Tess DA, Feng B, Litchfield J, Varma MV. Quantitative prediction of human renal clearance and drug-drug interactions of organic anion transporter substrates using in vitro transport data: a relative activity factor approach. Drug Metab Dispos. 2017;45(4):409\u201317.","journal-title":"Drug Metab Dispos"},{"issue":"3","key":"2964_CR6","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/j.1365-2125.2006.02655.x","volume":"62","author":"S Vormfelde","year":"2006","unstructured":"Vormfelde S, Schirmer M, Hagos Y, Toliat M, Engelhardt S, Meineke I, et al. Torsemide renal clearance and genetic variation in luminal and basolateral organic anion transporters. Br J Clin Pharmacol. 2006;62(3):323\u201335.","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"2964_CR7","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/S0009-9236(03)00060-2","volume":"73","author":"Y Nishizato","year":"2003","unstructured":"Nishizato Y, Ieiri I, Suzuki H, Kimura M, Kawabata K, Hirota T, et al. Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics. Clin Pharmacol Ther. 2003;73(6):554\u201365.","journal-title":"Clin Pharmacol Ther"},{"key":"2964_CR8","unstructured":"U.S. Food and Drug Administration. Drug development and drug interactions: table of substrates, inhibitors and inducers. 2017 [cited 2020 May 19]. Available from: https:\/\/www.fda.gov\/Drugs\/DevelopmentApprovalProcess\/DevelopmentResources\/DrugInteractionsLabeling\/ucm093664.htm"},{"issue":"2","key":"2964_CR9","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1021\/acs.molpharmaceut.5b00664","volume":"13","author":"S Izumi","year":"2016","unstructured":"Izumi S, Nozaki Y, Komori T, Takenaka O, Maeda K, Kusuhara H, et al. Investigation of fluorescein derivatives as substrates of organic anion transporting polypeptide (OATP) 1B1 to develop sensitive fluorescence-based OATP1B1 inhibition assays. Mol Pharm. 2016;13(2):438\u201348.","journal-title":"Mol Pharm"},{"issue":"10","key":"2964_CR10","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1124\/dmd.108.021410","volume":"36","author":"S Kitamura","year":"2008","unstructured":"Kitamura S, Maeda K, Wang Y, Sugiyama Y. Involvement of multiple transporters in the Hepatobiliary transport of Rosuvastatin. Drug Metab Dispos. 2008;36(10):2014\u201323.","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"2964_CR11","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1124\/jpet.102.043026","volume":"304","author":"R Tirona","year":"2003","unstructured":"Tirona R, Leake B, Wolkoff A, Kim R. Human organic anion transporting polypeptide-C (SLC21A6) is a major determinant of rifampin-mediated pregnane X receptor activation. J Pharmacol Exp Ther. 2003;304(1):223\u20138.","journal-title":"J Pharmacol Exp Ther"},{"key":"2964_CR12","unstructured":"European Medicines Agency. Guideline on the reporting of physiologically based pharmacokinetic (PBPK) modelling and simulation. 2018."},{"key":"2964_CR13","unstructured":"U.S. Food and Drug Administration. Clinical Drug Interaction Studies - Study Design, Data Analysis, Implications for Dosing, and Labeling Recommendations. Draft Guidance for Industry. 2017."},{"key":"2964_CR14","unstructured":"U.S. Food and Drug Administration. Physiologically Based Pharmacokinetic Analyses - Format and Content. Guidance for Industry. 2018."},{"issue":"12","key":"2964_CR15","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1124\/dmd.116.071472","volume":"44","author":"Y Tsuruya","year":"2016","unstructured":"Tsuruya Y, Kato K, Sano Y, Imamura Y, Maeda K, Kumagai Y, et al. Investigation of endogenous compounds applicable to drug-drug interaction studies involving the renal organic anion transporters, OAT1 and OAT3, in humans. Drug Metab Dispos. 2016;44(12):1825\u2013933.","journal-title":"Drug Metab Dispos"},{"issue":"3","key":"2964_CR16","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1681\/ASN.V133595","volume":"13","author":"RAMH Van Aubel","year":"2002","unstructured":"Van Aubel RAMH, Smeets PHE, Peters JGP, Bindels RJM, Russel FGM. The MRP4\/ABCC4 gene encodes a novel apical organic anion transporter in human kidney proximal tubules: putative efflux pump for urinary cAMP and cGMP. J Am Soc Nephrol. 2002;13(3):595\u2013603.","journal-title":"J Am Soc Nephrol"},{"issue":"February","key":"2964_CR17","first-page":"1","volume":"2","author":"T Eissing","year":"2011","unstructured":"Eissing T, Kuepfer L, Becker C, Block M, Coboeken K, Gaub T, et al. A computational systems biology software platform for multiscale modeling and simulation: integrating whole-body physiology, disease biology, and molecular reaction networks. Front Physiol. 2011;2(February):1\u201310.","journal-title":"Front Physiol"},{"issue":"12","key":"2964_CR18","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1002\/psp4.12473","volume":"8","author":"J Lippert","year":"2019","unstructured":"Lippert J, Burghaus R, Edginton A, Frechen S, Karlsson M, Kovar A, et al. Open systems pharmacology community - an open access, open source, open science approach to modeling and simulation in pharmaceutical sciences. CPT Pharmacometrics Syst Pharmacol. 2019;8(12):878\u201382.","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"6","key":"2964_CR19","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1002\/psp4.12511","volume":"9","author":"J Wojtyniak","year":"2020","unstructured":"Wojtyniak J, Britz H, Selzer D, Schwab M, Lehr T. Data digitizing: accurate and precise data extraction for quantitative systems pharmacology and physiologically-based pharmacokinetic modeling. CPT Pharmacometrics Syst Pharmacol. 2020;9(6):322\u201331.","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"2964_CR20","unstructured":"Open Systems Pharmacology Suite Community. Open Systems Pharmacology Suite Manual. 2018 [cited 2020 May 19]. Available from: https:\/\/docs.open-systems-pharmacology.org\/"},{"issue":"3\u20134","key":"2964_CR21","first-page":"5","volume":"32","author":"J Valentin","year":"2002","unstructured":"Valentin J. Basic anatomical and physiological data for use in radiological protection: reference values. A report of age- and gender-related differences in the anatomical and physiological characteristics of reference individuals. ICRP publication 89. Ann ICRP. 2002;32(3\u20134):5\u2013265.","journal-title":"Ann ICRP"},{"issue":"3","key":"2964_CR22","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s10928-007-9053-5","volume":"34","author":"S Willmann","year":"2007","unstructured":"Willmann S, H\u00f6hn K, Edginton A, Sevestre M, Solodenko J, Weiss W, et al. Development of a physiology-based whole-body population model for assessing the influence of individual variability on the pharmacokinetics of drugs. J Pharmacokinet Pharmacodyn. 2007;34(3):401\u201331.","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"5","key":"2964_CR23","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1124\/dmd.111.043174","volume":"40","author":"M Meyer","year":"2012","unstructured":"Meyer M, Schneckener S, Ludewig B, Kuepfer L, Lippert J. Using expression data for quantification of active processes in physiologically based pharmacokinetic modeling. Drug Metab Dispos. 2012;40(5):892\u2013901.","journal-title":"Drug Metab Dispos"},{"key":"2964_CR24","unstructured":"Tanaka G, Kawamura H. Anatomical and physiological characteristics for asian reference man: male and female of different ages: Tanaka model. Division of Radioecology National Institute of Radiological Sciences Hitachinaka 311\u201312 Japan. 1996;NIRS-M-115."},{"key":"2964_CR25","unstructured":"Open Systems Pharmacology Suite Community. PK-Sim\u00ae Ontogeny Database Documentation, Version 7.3. 2018 [cited 2020 May 19]. Available from: https:\/\/github.com\/Open-Systems-Pharmacology\/OSPSuite.Documentation\/blob\/master\/PK-Sim Ontogeny Database Version 7.3.pdf."},{"issue":"10","key":"2964_CR26","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1002\/psp4.12343","volume":"7","author":"N Hanke","year":"2018","unstructured":"Hanke N, Frechen S, Moj D, Britz H, Eissing T, Wendl T, et al. PBPK models for CYP3A4 and P-gp DDI prediction: a modeling network of rifampicin, itraconazole, clarithromycin, midazolam, alfentanil, and digoxin. CPT Pharmacometrics Syst Pharmacol. 2018;7(10):647\u201359.","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"2964_CR27","unstructured":"Open Systems Pharmacology. OSP repository. 2020 [cited 2020 May 19]. Available from: https:\/\/github.com\/Open-Systems-Pharmacology"},{"issue":"12","key":"2964_CR28","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1007\/s40262-019-00777-x","volume":"58","author":"D T\u00fcrk","year":"2019","unstructured":"T\u00fcrk D, Hanke N, Wolf S, Frechen S, Eissing T, Wendl T, et al. Physiologically based pharmacokinetic models for prediction of complex CYP2C8 and OATP1B1 (SLCO1B1) drug\u2013drug\u2013gene interactions: a modeling network of gemfibrozil, repaglinide, pioglitazone, rifampicin, clarithromycin and itraconazole. Clin Pharmacokinet. 2019;58(12):1595\u2013607.","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"2964_CR29","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1002\/psp4.12397","volume":"8","author":"H Britz","year":"2019","unstructured":"Britz H, Hanke N, Volz A, Spigset O, Schwab M, Eissing T, et al. Physiologically-based pharmacokinetic models for CYP1A2 drug-drug interaction prediction: a modeling network of fluvoxamine, theophylline, caffeine, rifampicin, and midazolam. CPT Pharmacometrics Syst Pharmacol. 2019;8(5):296\u2013307.","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"6","key":"2964_CR30","doi-asserted-by":"crossref","first-page":"556","DOI":"10.3390\/pharmaceutics12060556","volume":"12","author":"N Hanke","year":"2020","unstructured":"Hanke N, T\u00fcrk D, Selzer D, Wiebe S, Fernandez \u00c9, Stopfer P, et al. A mechanistic, Enantioselective, physiologically based pharmacokinetic model of verapamil and Norverapamil, built and evaluated for drug\u2013drug interaction studies. Pharmaceutics. 2020;12(6):556.","journal-title":"Pharmaceutics."},{"issue":"6","key":"2964_CR31","first-page":"578","volume":"12","author":"L Kovar","year":"2020","unstructured":"Kovar L, Schr\u00e4pel C, Selzer D, Kohl Y, Bals R, Schwab M, et al. Physiologically-based pharmacokinetic (PBPK) modeling of buprenorphine in adults. Children and Preterm Neonates Pharmaceutics. 2020;12(6):578.","journal-title":"Children and Preterm Neonates Pharmaceutics"},{"key":"2964_CR32","doi-asserted-by":"crossref","unstructured":"Wiebe S, Giessmann T, Hohl K, Schmidt-Gerets S, Hauel E, Jambrecina A, et al. Validation of a drug transporter probe cocktail using the prototypical inhibitors rifampin, probenecid, verapamil, and cimetidine. Clin Pharmacokinet. 2020.","DOI":"10.1007\/s40262-020-00907-w"},{"key":"2964_CR33","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.ejps.2017.05.055","volume":"106","author":"K Ball","year":"2017","unstructured":"Ball K, Jamier T, Parmentier Y, Denizot C, Mallier A, Chenel M. Prediction of renal transporter-mediated drug-drug interactions for a drug which is an OAT substrate and inhibitor using PBPK modelling. Eur J Pharm Sci. 2017;106:122\u201332.","journal-title":"Eur J Pharm Sci"},{"key":"2964_CR34","doi-asserted-by":"crossref","unstructured":"Hsu V, de L. T. Vieira M, Zhao P, Zhang L, Zheng J, Nordmark A, et al. Towards quantitation of the effects of renal impairment and probenecid inhibition on kidney uptake and efflux transporters, using physiologically based pharmacokinetic modelling and simulations. Clin Pharmacokinet 2014;53(3):283\u2013293.","DOI":"10.1007\/s40262-013-0117-y"},{"issue":"6","key":"2964_CR35","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1111\/cts.12486","volume":"10","author":"M Posada","year":"2017","unstructured":"Posada M, Cannady E, Payne C, Zhang X, Bacon J, Pak Y, et al. Prediction of transporter-mediated drug-drug interactions for baricitinib. Clin Transl Sci. 2017;10(6):509\u201319.","journal-title":"Clin Transl Sci"},{"issue":"12","key":"2964_CR36","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1111\/jphp.12618","volume":"68","author":"S Hansmann","year":"2016","unstructured":"Hansmann S, Darwich A, Margolskee A, Aarons L, Dressman J. Forecasting oral absorption across biopharmaceutics classification system classes with physiologically based pharmacokinetic models. J Pharm Pharmacol. 2016;68(12):1501\u201315.","journal-title":"J Pharm Pharmacol"},{"issue":"5","key":"2964_CR37","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1111\/jphp.12365","volume":"67","author":"K Otsuka","year":"2015","unstructured":"Otsuka K, Wagner C, Selen A, Dressman J. Prediction of in-vivo pharmacokinetic profile for immediate and modified release oral dosage forms of furosemide using an in-vitro-in-silico-in-vivo approach. J Pharm Pharmacol. 2015;67(5):651\u201365.","journal-title":"J Pharm Pharmacol"},{"issue":"12","key":"2964_CR38","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1007\/s40262-016-0422-3","volume":"55","author":"J Schlender","year":"2016","unstructured":"Schlender J, Meyer M, Thelen K, Krauss M, Willmann S, Eissing T, et al. Development of a whole-body physiologically based pharmacokinetic approach to assess the pharmacokinetics of drugs in elderly individuals. Clin Pharmacokinet. 2016;55(12):1573\u201389.","journal-title":"Clin Pharmacokinet"},{"issue":"12","key":"2964_CR39","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1124\/dmd.114.059485","volume":"42","author":"Y Ito","year":"2014","unstructured":"Ito Y, Fukami T, Yokoi T, Nakajima M. An orphan esterase ABHD10 modulates probenecid acyl glucuronidation in human liver. Drug Metab Dispos. 2014;42(12):2109\u201316.","journal-title":"Drug Metab Dispos"},{"issue":"4","key":"2964_CR40","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1124\/dmd.114.062877","volume":"43","author":"G Margaillan","year":"2015","unstructured":"Margaillan G, Rouleau M, Fallon JK, Caron P, Villeneuve L, Turcotte V, et al. Quantitative profiling of human renal UDP-glucuronosyltransferases and glucuronidation activity: a comparison of normal and tumoral kidney tissues. Drug Metab Dispos. 2015;43(4):611\u20139.","journal-title":"Drug Metab Dispos"},{"issue":"6887","key":"2964_CR41","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/nature742","volume":"417","author":"A Enomoto","year":"2002","unstructured":"Enomoto A, Kimura H, Chairoungdua A, Shigeta Y, Jutabha P, Cha SH, et al. Molecular identification of a renal urate-anion exchanger that regulates blood urate levels. Nature. 2002;417(6887):447\u201352.","journal-title":"Nature."},{"key":"2964_CR42","first-page":"278","volume":"140","author":"P Dayton","year":"1963","unstructured":"Dayton P, Yu T, Chen W, Berger L, West L, Gutman A. The physiological disposition of probenecid, including renal clearance, in man, studied by an improved method for its estimation in biological material. J Pharmacol Exp Ther. 1963;140:278\u201386.","journal-title":"J Pharmacol Exp Ther"},{"issue":"5","key":"2964_CR43","first-page":"325","volume":"14","author":"T Vree","year":"1992","unstructured":"Vree T, Van Ewijk-Beneken KE, Wuis E, Hekster Y. Capacity-limited renal glucuronidation of probenecid by humans. A pilot Vmax-finding study. Pharm Weekbl Sci. 1992;14(5):325\u201331.","journal-title":"Pharm Weekbl Sci"},{"issue":"5","key":"2964_CR44","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/BF01880626","volume":"15","author":"T Vree","year":"1993","unstructured":"Vree T, Van Ewijk-Beneken KE, Wuis E, Hekster Y, Broekman M. Interindividual variation in the capacity-limited renal glucuronidation of probenecid by humans. Pharm World Sci. 1993;15(5):197\u2013202.","journal-title":"Pharm World Sci"},{"issue":"6","key":"2964_CR45","doi-asserted-by":"crossref","first-page":"2544","DOI":"10.1002\/jps.22030","volume":"99","author":"G Granero","year":"2010","unstructured":"Granero G, Longhi M, Mora M, Junginger H, Midha K, Shah V, et al. Biowaiver monographs for immediate release solid oral dosage forms: furosemide. J Pharm Sci. 2010;99(6):2544\u201356.","journal-title":"J Pharm Sci"},{"issue":"5","key":"2964_CR46","doi-asserted-by":"crossref","first-page":"381","DOI":"10.2165\/00003088-199018050-00004","volume":"18","author":"L Ponto","year":"1990","unstructured":"Ponto L, Schoenwald R. Furosemide (frusemide). A pharmacokinetic\/pharmacodynamic review (part I). Clin Pharmacokinet. 1990;18(5):381\u2013408.","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"2964_CR47","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1002\/jps.10099","volume":"91","author":"S Flanagan","year":"2002","unstructured":"Flanagan S, Takahashi L, Liu X, Benet L. Contributions of saturable active secretion, passive transcellular, and paracellular diffusion to the overall transport of furosemide across adenocarcinoma (Caco-2) cells. J Pharm Sci. 2002;91(4):1169\u201377.","journal-title":"J Pharm Sci"},{"issue":"2","key":"2964_CR48","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1006\/bbrc.2001.4774","volume":"283","author":"W Sun","year":"2001","unstructured":"Sun W, Wu R, Van Poelje P, Erion M. Isolation of a family of organic anion transporters from human liver and kidney. Biochem Biophys Res Commun. 2001;283(2):417\u201322.","journal-title":"Biochem Biophys Res Commun"},{"issue":"9","key":"2964_CR49","doi-asserted-by":"crossref","first-page":"3220","DOI":"10.1002\/jps.24489","volume":"104","author":"T Ebner","year":"2015","unstructured":"Ebner T, Ishiguro N, Taub M. The use of transporter probe drug cocktails for the assessment of transporter-based drug\u2013drug interactions in a clinical setting - proposal of a four component transporter cocktail. J Pharm Sci. 2015;104(9):3220\u20138.","journal-title":"J Pharm Sci"},{"issue":"2","key":"2964_CR50","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.bcp.2008.04.014","volume":"76","author":"O Kerdpin","year":"2008","unstructured":"Kerdpin O, Knights KM, Elliot DJ, Miners JO. In vitro characterisation of human renal and hepatic frusemide glucuronidation and identification of the UDP-glucuronosyltransferase enzymes involved in this pathway. Biochem Pharmacol. 2008;76(2):249\u201357.","journal-title":"Biochem Pharmacol"},{"issue":"1","key":"2964_CR51","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1681\/ASN.2005090966","volume":"18","author":"M Hasegawa","year":"2007","unstructured":"Hasegawa M, Kusuhara H, Adachi M, Schuetz J, Takeuchi K, Sugiyama Y. Multidrug resistance-associated protein 4 is involved in the urinary excretion of hydrochlorothiazide and furosemide. J Am Soc Nephrol. 2007;18(1):37\u201345.","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"2964_CR52","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1159\/000056161","volume":"64","author":"S Flanagan","year":"2002","unstructured":"Flanagan S, Cummins C, Susanto M, Liu X, Takahashi L, Benet L. Comparison of furosemide and vinblastine secretion from cell lines overexpressing multidrug resistance protein (P-glycoprotein) and multidrug resistance-associated proteins (MRP1 and MRP2). Pharmacology. 2002;64(3):126\u201334.","journal-title":"Pharmacology."},{"issue":"2","key":"2964_CR53","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1124\/dmd.114.059105","volume":"43","author":"S Izumi","year":"2015","unstructured":"Izumi S, Nozaki Y, Maeda K, Komori T, Takenaka O, Kusuhara H, et al. Investigation of the impact of substrate selection on in vitro organic anion transporting polypeptide 1B1 inhibition profiles for the prediction of drug-drug interactions. Drug Metab Dispos. 2015;43(2):235\u201347.","journal-title":"Drug Metab Dispos"},{"issue":"2","key":"2964_CR54","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/j.1365-2125.2009.03564.x","volume":"69","author":"C Landersdorfer","year":"2010","unstructured":"Landersdorfer C, Kirkpatrick C, Kinzig M, Bulitta J, Holzgrabe U, Jaehde U, et al. Competitive inhibition of renal tubular secretion of ciprofloxacin and metabolite by probenecid. Br J Clin Pharmacol. 2010;69(2):167\u201378.","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"2964_CR55","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/BF00543976","volume":"32","author":"B Emanuelsson","year":"1987","unstructured":"Emanuelsson B, Beermann B, Paalzow L. Non-linear elimination and protein binding of probenecid. Eur J Clin Pharmacol. 1987;32(4):395\u2013401.","journal-title":"Eur J Clin Pharmacol"},{"issue":"2","key":"2964_CR56","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/j.1365-2125.1977.tb00682.x","volume":"4","author":"R Branch","year":"1977","unstructured":"Branch R, Roberts C, Homeida M, Levine D. Determinants of response to frusemide in normal subjects. Br J Clin Pharmacol. 1977;4(2):121\u20137.","journal-title":"Br J Clin Pharmacol"},{"key":"2964_CR57","unstructured":"U.S. Food and Drug Administration. Clinical Pharmacology and Biopharmaceutics Review - NDA: 21\u2013913 - part 2. 2006. p. 163\u2013362."},{"issue":"2","key":"2964_CR58","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1002\/bod.2510090209","volume":"9","author":"E Waller","year":"1988","unstructured":"Waller E, Crismon M, Smith R, Bauza M, Doluisio J. Comparative bioavailability of furosemide from solution and 40 mg tablets with different dissolution characteristics following oral administration in normal men. Biopharm Drug Dispos. 1988;9(2):211\u20138.","journal-title":"Biopharm Drug Dispos"},{"issue":"5","key":"2964_CR59","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1002\/jps.2600690526","volume":"69","author":"D Smith","year":"1980","unstructured":"Smith D, Gee W, Brater D, Lin E, Benet L. Preliminary evaluation of furosemide\u2013probenecid interaction in humans. J Pharm Sci. 1980;69(5):571\u20135.","journal-title":"J Pharm Sci"},{"key":"2964_CR60","doi-asserted-by":"crossref","unstructured":"Kenwright S, Levi AJ. Impairment of hepatic uptake of rifamycin antibiotics by probenecid, and its therapeutic implications. Lancet (London, England). 1973;2(7843):1401\u20135.","DOI":"10.1016\/S0140-6736(73)92799-2"},{"issue":"2","key":"2964_CR61","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1124\/dmd.110.036103","volume":"39","author":"E Guest","year":"2011","unstructured":"Guest E, Aarons L, Houston J, Rostami-Hodjegan A, Galetin A. Critique of the two-fold measure of prediction success for ratios: application for the assessment of drug-drug interactions. Drug Metab Dispos. 2011;39(2):170\u20133.","journal-title":"Drug Metab Dispos"},{"issue":"4","key":"2964_CR62","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1002\/cpt1977224402","volume":"22","author":"M Homeida","year":"1977","unstructured":"Homeida M, Roberts C, Branch R. Influence of probenecid and spironolactone on furosemide kinetics and dynamics in man. Clin Pharmacol Ther. 1977;22(4):402\u20139.","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"2964_CR63","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1124\/jpet.118.252643","volume":"368","author":"H Shen","year":"2019","unstructured":"Shen H, Holenarsipur V, Mariappan T, Drexler D, Cantone J, Rajanna P, et al. Evidence for the validity of pyridoxic acid (PDA) as a plasma-based endogenous probe for OAT1 and OAT3 function in healthy subjects. J Pharmacol Exp Ther. 2019;368(1):136\u201345.","journal-title":"J Pharmacol Exp Ther"},{"issue":"6","key":"2964_CR64","first-page":"692","volume":"39","author":"T Vree","year":"1995","unstructured":"Vree T, van den Biggelaar-Martea M, Verwey-van WC. Probenecid inhibits the renal clearance of frusemide and its acyl glucuronide. Br J Clin Pharmacol. 1995;39(6):692\u20135.","journal-title":"Br J Clin Pharmacol"}],"container-title":["Pharmaceutical Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-020-02964-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11095-020-02964-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-020-02964-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,29]],"date-time":"2022-11-29T15:15:29Z","timestamp":1669734929000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11095-020-02964-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,25]]},"references-count":64,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["2964"],"URL":"https:\/\/doi.org\/10.1007\/s11095-020-02964-z","relation":{},"ISSN":["0724-8741","1573-904X"],"issn-type":[{"value":"0724-8741","type":"print"},{"value":"1573-904X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,25]]},"assertion":[{"value":"24 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"250"}}